48% of patients in trial had CKD class Chronic Heart Failure Treating Heart Failure NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3093-7 Study Intervention and comparison Population Outcomes Comments per day according to response Placebo HF: HF for at least 6 weeks, NYHA class III- IV and had been NYHA IV at some point in the previous 6 months, were being treated with an ACE inhibitor (if tolerated) and a loop diuretic, LVEF CKD subgroup: Subgroup status: Ejection fraction: All reduced NYHA class: Class III or IV Funded by industry SHIFT trial: Voors (Swedberg ) Ivabradine to a target dose of 7 5 mg twice daily according to heart rate Placebo according to heart rate Duration Median 23 months. N=1579 patients with CKD Pre-specified subgroup of multicentre trial HF: Adults in sinus rhythm 70 bpm. Stable symptomatic heart failure, admission for HF within the previous year, and an LVEF of CKD subgroup: Renal function Bradycardia Hyperkalaemia 10. 26% of patients in trial had CKD stage Subgroup status: Ejection fraction: All reduced NYHA class: Mixed Funded by industry DIG trial: Shlipak (DIG ) Digoxin. An algorithm based on age, gender, weight and creatinine levels determined doses of digoxin. Placebo Duration mean 3 years N=3157 patients with CKD Subgroup analysis of multicentre North American trial HF: Stable heart failure and left ventricular ejection fraction <45% and were in sinus rhythm CKD subgroup: Two strata eGFR 30-59, stage eGFR ~20a Mortality Hospitalisation Recruited 1991-93. 46% of patients in trial had CKD (3% Subgroup status: Ejection fraction: All reduced NYHA class: Mixed Chronic Heart Failure Treating Heart Failure NICE 2018. All rights reserved. Subject to Notice of rights. 